A Retrospective Study of First‐Line Immunotherapy for Advanced Non‐Small Cell Lung Cancer in the Elderly
Age may not be the main prognostic factor for the effectiveness of first-line immunotherapy in patients with advanced NSCLC. Longer mOS was observed in patients who were non-smokers, had no bone metastases, exhibited PD-L1 TPS ≥ 50%, and had a higher prognostic nutritional index (PNI), regardless of age. Furthermore, the efficacy and safety profiles of pembrolizumab plus CT versus tislelizumab plus CT show no differences in the treatment of advanced NSCLC.
Authors
- Sheng Hsiung Yang (ORCID: https://orcid.org/0000-0003-1869-3100)
- Kui Xiao (ORCID: https://orcid.org/0000-0003-4475-0893)
- Sy Liu
- Yalin Zhu
Institutions
- Central South University (CN)
- Changsha Medical University (CN)
- Hunan Provincial Center for Disease Control and Prevention (CN)
- Second Xiangya Hospital of Central South University (CN)
Publication Details
- Journal
- Aging Medicine
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/agm2.70052
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00